hotspot -WSS

hotspot

author：leisure time 2025-10-01 17:20:17 - browse：42379

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： My daughter's legacy lives on through her writing, phage therapy

hotspot

WSS

Hospitals need to get ahead of regulations on climate change

NIH tests clinical research in primary care with $30 million program

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

STAT Virtual Event: ASCO Recap, Live!

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Stephen Quake on the Chan Zuckerberg quest to conquer disease

hotspot

hotspot

hotspot

In Memoriam: Notable people who died in 2023

Protect nursing home residents from future pandemics

United colonoscopy coverage change 'may cost lives,' doctors say

Why some fertility treatments produce more boy babies

Psychedelics group wrestles with new pharma identity

Teladoc has a new CEO, but challenges remain the same

Apple is now the first public company to be valued at $3 trillion

Louisiana bill approved classifying abortion pills as controlled substances

Tori Bowie and the unacceptable rates of Black maternal death

Decentralized clinical trials need collaboration to achieve wider use

leisure time

J&J reports mixed data on next

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Readers discuss the intersection of pregnancy and addiction

Report captures long Covid’s disabling effects and policy challenges

Unmasking the 'centricity' illusion in clinical trials

Study: Why relieving medical debt did not improve financial outcomes

hotspot

hotspot

hotspot

focus